A high expression of TGF-β in CRC tissues has been correlated with tumor progression, neo-angiogenesis, lymph-node metastases, and immunosuppression, as well as poor prognosis and adverse clinical outcomes [53,54,55]. The gene discussed is TGFB1; the disease is neoplasm.